More Stories

Informist, Friday, Apr. 10, 2026

 

MUMBAI – Shares of pharmaceutical companies are seen in range next week. Investors will continue to move away from healthcare-related stocks if, as they hope and expect, Iran and the US reach a firm peace pact over the weekend, improving risk appetite and lowering demand for defensive sectors, an analyst at a domestic brokerage said. Pharma stocks may not see fresh buying interest next week ahead of their March quarter earnings, which are likely be flat for most, with lower sales in the US cancelling healthy growth in other regions.

 

Nuvama Institutional Equities expects 3% year-on-year growth in the net profit of the pharmaceutical companies that it tracks. The domestic business revenue is expected to expand 12% on year for these companies, supported by the strong performance of cardiac and anti-diabetes therapies. The brokerage expects sales in the US of Dr. Reddy's Laboratories, Cipla, and Zydus Lifesciences to be hit by higher exposure to generic Revlimid sales. The drug has been seeing sharp price erosion with each successive quarter. In fact, the brokerage sees no generic Revlimid sales for Aurobindo Pharma. Lanreotide supply issues are also likely to add to Cipla's woes in the March quarter, it said.

 

Kotak Securities expects 1% year-on-year growth in earnings before interest, taxes, depreciation, and amortisation for pharmaceutical companies owing to a high base effect in generic Revlimid sales. It sees healthy growth in India as well as in non-US markets, given the weakness in the rupee. For contract development and manufacturing companies, the brokerage expects flattish sales growth in the quarter. Generic active pharmaceutical ingredient makers will see a slight sequential volume uptick, the brokerage said. The war in West Asia will have minimal impact with companies usually holding raw material inventory of 1-3 months, the brokerage said.

 

Prabhudas Lilladher sees around 1% growth in EBITDA for companies under its coverage. The brokerage also sees low generic Revlimid sales being the primary drag on the US business. "From a profitability standpoint, tailwinds from currency movements will be partly offset by higher freight costs toward the end of the quarter, given the Middle East (West Asia) conflict," the brokerage said. The domestic formulations business is expected to remain healthier on the back of improving demand for acute therapies and continued traction in chronic therapies.

 

This week, Nifty Pharma gained the least among sectoral indices in a strong market, rising just 1.6% to 22164.85 points. "The index is still consolidating within the band of 21000–23500 points," Rupak De, technical analyst at LKP Securities said. However, he added that so far in 2026, Laurus Labs, Lupin, and Glenmark Pharmaceuticals have outperformed their peers.

 

TOP HEADLINES

* Govt says pharma cos not facing supply disruption due to West Asia crisis
* Glenmark Pharma gets US FDA final nod for progesterone vaginal inserts
* Lupin gets US FDA nod for Dapagliflozin, Metformin Hydrochloride tablets
* Zydus Life gets US FDA final nod to market Dapagliflozin tablets in US
* Biocon arm, Lupin get US FDA approval for dapagliflozin tablets
* Aurobindo Pharma gets US FDA final nod to make, sell dapagliflozin tablets
* Semaglutide demand low despite price cut, generic launches, says pharmacists
* Biocon starts sale of denosumab biosimilars Bosaya, Aukelso in US
* Alkem Lab launches multivitamin supplement A to Z Daily for adults
* Aurobindo Pharma arm's Xolair biosimilar phase 3 study saw positive results
* Aurobindo Pharma to buy back 5.4 mln shr at INR 1,475/shr, record date Apr 17
* US FDA issues 4 observations to Granules India's US arm Granules Pharma unit
* IPO Alert: Sai Parenteral's ends 3.5% higher on NSE after listing at premium
* Emcure Pharma cuts Poviztra semaglutide drug prices by up to 55%

 

Following are the resistance and support levels for key pharmaceutical stocks for next week as per calculations based on their prices on the National Stock Exchange:

 

Company	Price	Week-on-Week Change in %	Resistance	Support
Abbott India	25,780.00	(-)1.90	26,140.00	25,440.00
Alkem Laboratories	5,440.00	3.50	5,513.00	5,317.00
Aurobindo Pharma	1,349.40	1.20	1,365.30	1,328.90
Biocon	348.60	(-)1.10	352.80	344.00
Cipla	1,229.50	3.10	1,248.00	1,211.60
Divi's Laboratories	6,116.50	4.40	6,258.20	5,860.20
Dr. Reddy's Laboratories	1,232.20	1.20	1,253.90	1,197.90
Gland Pharma	1,741.90	3.20	1,787.30	1,709.30
GlaxoSmithKline Pharmaceuticals	2,394.00	3.60	2,469.10	2,319.50
Glenmark Pharmaceuticals	2,163.20	3.40	2,220.30	2,120.30
Granules India	631.95	3.00	654.60	617.30
Ipca Laboratories	1,456.20	(-)2.20	1,473.20	1,441.80
Laurus Labs	1,098.35	5.30	1,125.10	1,066.30
Lupin	2,333.80	2.60	2,366.40	2,273.80
Natco Pharma	1,104.20	7.50	1,147.90	1,078.20
Pfizer	4,868.60	(-)0.40	4,957.50	4,705.50
Sanofi India	3,491.90	7.00	3,533.30	3,436.30
Sun Pharmaceutical Industries	1,654.90	(-)2.30	1,731.40	1,592.20
Torrent Pharmaceuticals	4,155.20	4.20	4,215.30	4,044.50
Zydus Lifesciences	915.40	5.90	927.80	893.80
Index	Level
Nifty Pharma	22164.85	1.60	22355.30	21837.60
Nifty 50	24050.60	5.90	24211.40	23776.00
S&P Bse Sensex	77550.25	5.80	78112.60	76570.00

 

End

 

Reported by Eshitva Prakash

Edited by Rajeev Pai

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.